Home tDCS for the Treatment of Major Depression: A Randomised Clinical Trial
The purpose of this multicentric randomized controlled trial is to compare the effectiveness and safety of home-based tDCS for the treatment of major depression versus tDCS treatment in a healthcare centre, and explore the effects of an accelerated home-tDCS protocol. The change in depression index at the end of treatment, measured with MADRS, will be the primary outcome.
• Spanish or Catalan speakers of both sexes between the ages of 18 and 65.
• Patients diagnosed with major depression, based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Specifically, patients will be included who meet the criteria for a major depressive episode with a longitudinal diagnosis of major depressive disorder, single or recurrent episode; or bipolar disorder type 1 or 2. Patients must obtain a moderate or higher score, therefore we establish a lower limit of 15 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Alonzo et al., 2019).
• Patients receiving or not receiving pharmacological treatment for depression will be included, and this will be recorded as an additional variable.
• Have the ability and willingness to commit to the study team for supervision of the intervention sessions and close monitoring of safety.
• Demonstrate the acquisition of the ability to properly apply home tDCS independently or with the help of a companion.